메뉴 건너뛰기




Volumn 51, Issue 4, 2016, Pages 372-378

One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis

Author keywords

Cystic fibrosis; forced expiratory volume in one second; long term safety; Pseudomonas aeruginosa; tobramycin powder for inhalation

Indexed keywords

CREATININE; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT; POWDER;

EID: 84952877731     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23358     Document Type: Article
Times cited : (17)

References (9)
  • 1
    • 84961402582 scopus 로고    scopus 로고
    • 2015 09 January
    • CFF Patient Registry annual data report 2012. http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf. 09 January, 2015.
    • (2012) CFF Patient Registry Annual Data Report
  • 2
    • 0036320272 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    • Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
    • (2002) Pediatr Pulmonol , vol.34 , pp. 91-100
    • Emerson, J.1    Rosenfeld, M.2    McNamara, S.3    Ramsey, B.4    Gibson, R.L.5
  • 3
    • 3343023861 scopus 로고    scopus 로고
    • Early intervention and prevention of lung disease in cystic fibrosis: A European consensus
    • Doring G, Hoiby N, Consensus Study G,. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67-91.
    • (2004) J Cyst Fibros , vol.3 , pp. 67-91
    • Doring, G.1    Hoiby, N.2    Consensus, S.G.3
  • 5
    • 84900031485 scopus 로고    scopus 로고
    • Clinical use of tobramycin inhalation solution (TOBI(R)) shows sustained improvement in FEV1 in cystic fibrosis
    • Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Morgan WJ,. Clinical use of tobramycin inhalation solution (TOBI(R)) shows sustained improvement in FEV1 in cystic fibrosis. Pediatr Pulmonol 2014; 49: 529-536.
    • (2014) Pediatr Pulmonol , vol.49 , pp. 529-536
    • Konstan, M.W.1    Wagener, J.S.2    Pasta, D.J.3    Millar, S.J.4    Morgan, W.J.5
  • 7
    • 79951840468 scopus 로고    scopus 로고
    • Tobramycin inhalation powder for P. Aeruginosa infection in cystic fibrosis: The EVOLVE trial
    • Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G,. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46: 230-238.
    • (2011) Pediatr Pulmonol , vol.46 , pp. 230-238
    • Konstan, M.W.1    Geller, D.E.2    Minic, P.3    Brockhaus, F.4    Zhang, J.5    Angyalosi, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.